−1.27USD
−88.48 MUSD
31.25 MUSD
64.47 M
About Aclaris Therapeutics, Inc.
Sector
CEO
Neal S. Walker
Headquarters
Wayne
Website
Employees (FY)
91
Founded
2012
FIGI
BBG003LF0QR9
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ACRS is 1.22 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aclaris Therapeutics, Inc. stocks are traded under the ticker ACRS.
Aclaris Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ACRS stock is 2.88% volatile and has beta coefficient of 1.10. Check out the list of the most volatile stocks — is Aclaris Therapeutics, Inc. there?
ACRS earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.48 USD resulting in a 14.55% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about Aclaris Therapeutics, Inc. earnings.
Aclaris Therapeutics, Inc. revenue for the last quarter amounts to 9.28 M USD despite the estimated figure of 1.57 M USD. In the next quarter revenue is expected to reach 4.66 M USD.
Yes, you can track Aclaris Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ACRS stock has fallen by 0.81% compared to the previous week, the month change is a 1.67% rise, over the last year Aclaris Therapeutics, Inc. has showed a 86.61% decrease.
ACRS net income for the last quarter is −1.49 M USD, while the quarter before that showed −29.26 M USD of net income which accounts for 94.90% change. Track more Aclaris Therapeutics, Inc. financial stats to get the full picture.
Today Aclaris Therapeutics, Inc. has the market capitalization of 86.53 M, it has decreased by 5.69% over the last week.
No, ACRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ACRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aclaris Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 91.00 employees. See our rating of the largest employees — is Aclaris Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aclaris Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aclaris Therapeutics, Inc. stock shows the sell signal. See more of Aclaris Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Aclaris Therapeutics, Inc. future price: according to them, ACRS price has a max estimate of 3.00 USD and a min estimate of 1.00 USD. Read a more detailed Aclaris Therapeutics, Inc. forecast: see what analysts think of Aclaris Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aclaris Therapeutics, Inc. EBITDA is −104.71 M USD, and current EBITDA margin is −363.74%. See more stats in Aclaris Therapeutics, Inc. financial statements.